c-Kit


all tumors : 3815 : HU subtypes p= <0.00001
357 152 482 289 257 344
Log2 Expression
Basal
HER2
LumA
LumB
Normal−like
Unclassified


all tumors : 3815 : PAM50 subtypes p= <0.00001
304 240 465 471 304 97
Log2 Expression
Basal
HER2enriched
LumA
LumB
Normal−like
Unclassified

YES


all tumors : 7525 : HU subtypes p= <0.00001
357 152 482 289 257 344
Log2 Expression
Basal
HER2
LumA
LumB
Normal−like
Unclassified


all tumors : 7525 : PAM50 subtypes p= <0.00001
304 240 465 471 304 97
Log2 Expression
Basal
HER2enriched
LumA
LumB
Normal−like
Unclassified

FYN


all tumors : 2534 : HU subtypes p= <0.00001
357 152 482 289 257 344
Log2 Expression
Basal
HER2
LumA
LumB
Normal−like
Unclassified


all tumors : 2534 : PAM50 subtypes p= <0.00001
304 240 465 471 304 97
Log2 Expression
Basal
HER2enriched
LumA
LumB
Normal−like
Unclassified

LCK


all tumors : 3932 : HU subtypes p= <0.00001
357 152 482 289 257 344
Log2 Expression
Basal
HER2
LumA
LumB
Normal−like
Unclassified


all tumors : 3932 : PAM50 subtypes p= <0.00001
304 240 465 471 304 97
Log2 Expression
Basal
HER2enriched
LumA
LumB
Normal−like
Unclassified

FRK


all tumors : 2444 : HU subtypes p= 2e−05
357 152 482 289 257 344
Log2 Expression
Basal
HER2
LumA
LumB
Normal−like
Unclassified


all tumors : 2444 : PAM50 subtypes p= 0.00013
304 240 465 471 304 97
Log2 Expression
Basal
ER2enriched
LumA
LumB
Normal−like
Unclassified

EGFR


all tumors : 1956 : HU subtypes p= <0.00001
357 152 482 289 257 344
Log2 Expression
Basal
HER2
LumA
LumB
Normal−like
Unclassified


all tumors : 1956 : PAM50 subtypes p= <0.00001
304 240 465 471 304 97
Log2 Expression
Basal
HER2enriched
LumA
LumB
Normal−like
Unclassified

LYN


all tumors : 4067 : HU subtypes p= <0.00001
357 152 482 289 257 344
Log2 Expression
Basal
HER2
LumA
LumB
Normal−like
Unclassified


all tumors : 4067 : PAM50 subtypes p= <0.00001
304 240 465 471 304 97
Log2 Expression
Basal
HER2enriched
LumA
LumB
Normal−like
Unclassified

BTK


all tumors : 695 : HU subtypes p= <0.00001
357 152 482 289 257 344
Log2 Expression
Basal
HER2
LumA
LumB
Normal−like
Unclassified


all tumors : 695 : PAM50 subtypes p= <0.00001
304 240 465 471 304 97
Log2 Expression
Basal
HER2enriched
LumA
LumB
Normal−like
Unclassified

ABL2


all tumors : 27 : HU subtypes p= <0.00001
357 152 482 289 257 344
Log2 Expression
Basal
HER2
LumA
LumB
Normal−like
Unclassified


all tumors : 27 : PAM50 subtypes p= 0.00142
304 240 465 471 304 97
Log2 Expression
Basal
HER2enriched
LumA
LumB
Normal−like
Unclassified

Figure S3. Expression of Receptor Tyrosine Kinases (RTKs) and intracellular tyrosine kinases in Breast Cancer. Expression of RTKs and intracellular tyrosine kinases targeted by Imatinib, Dasatinib, Sorafenib, Sunitinib, Nilotinib, and Lapatinib was explored using data from the Gene expression-based Outcome for Breast cancer Online (GOBO) tool. Differential expression of RTKs and intracellular tyrosine kinases among the basal, HER2-enriched, normal-like, and unclassified subgroups is shown. RTKs and intracellular tyrosine kinases showing significantly higher levels of expression in the basal subtype (LCK, YES, FYN, FRK, LYN, BTK, ABL, and c-Kit) were selected for further analysis.